This study aims to evaluate the efficacy and safety of recombinant human growth hormone injection in short stature children due to chronic kidney disease before transplantation.

Inclusion Criteria:

• Signed informed consent of the subjects or the legal guardian.
• Subjects and guardian are willing and able to cooperate to complete scheduled visits,treatment plans and laboratory tests and other procedures.
• Diagnosed as chronic kidney disease.
• Glomerular filtration rate (GFR) <75ml/per min/1.73m2.
• After the treatment and adjustment of hypertension, anemia, metabolic acidosis, malnutrition, renal osteopathy, hypothyroidism, etc..
• Chronological age: ≥2years and ≤14years.
• Height Standard Deviation Score(HtSDS) ≤-2SD for chronological age.
• Bone age: girls≤10 years; boys≤11years.
• Pre-pubertal (Tanner Stage I ) patients.
• No history of growth hormone treatment.

Exclusion Criteria:

• Subjects with abnormal liver functions.
• Subjects positive for anti-HBc, HbsAg or HbeAg in Hepatitis B virus tests.
• After adjustment heart function,Cardiac ejection fraction(EF) <50%.
• Subjects with highly allergic constitution or allergy to proteins or investigational product or its excipient.
• Subjects with systemic chronic disease or general infection or mental disease.
• Subjects with diabetes or impaired fasting glucose.
• Subjects with tumor or potential tumor.
• Subjects who are using glucocorticoid or immunosuppressant.
• Other causes for growth retardation.
• Inability to obtain accurate height measurements.
• Subjects who took part in other clinical trials within 3 months.
• Concomitant administration of other treatment that may have an effect on growth within 3 months.
• Other conditions which are unsuitable for this study in the opinion of the investigator.